Genome-wide multi-trait analysis of irritable bowel syndrome and related mental conditions identifies 38 new genetic hits

Silvia Alemany, María Soler Artigas, Judit Cabana, Dana Salim Fakhreddine, Natalia Llonga, Laura Vilar-Ribó, Amanda Rodríguez-Urrutia, Judit Palacio, Ana María González-Castro, Beatriz Lobo, Carmen Alonso-Cotoner, Magnus Simrén, Javier Santos, Josep Antoni Ramos-Quiroga, Marta Ribasés
doi: https://doi.org/10.1101/2023.01.30.23285080

ABSTRACT

Background Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction frequently accompanied by mental conditions, including depression and anxiety. Despite showing substantial heritability and being partly determined by a genetic component, the genetic underpinnings explaining the high rates of comorbidity remain largely unclear and there are no conclusive data on the temporal relationship between them. Exploring the overlapping genetic architecture between IBS and mental conditions may help to identify novel genetic loci and biological mechanisms underlying IBS and causal relationships between them.

Methods We quantified the genetic overlap between IBS, neuroticism, depression and anxiety, conducted a multi-trait genome-wide association study (GWAS) considering these traits and investigated causal relationships between them by using the largest GWAS to date.

Results IBS showed to be a highly polygenic disorder with extensive genetic sharing with mental conditions. Multi-trait analysis of IBS and neuroticism, depression and anxiety identified 42 genome-wide significant hits for IBS, of which 38 are novel. Fine-mapping risk loci highlighted 289 genes upregulated during early embryonic brain development and gene-sets related with psychiatric, digestive and autoimmune disorders. IBS-associated genes were enriched for target genes of anti-inflammatory and antirheumatic drugs, anesthetics and opioid dependence pharmacological treatment. Mendelian-randomization analysis accounting for correlated pleiotropy identified bidirectional causal effects between IBS and neuroticism and depression and causal effects of the genetic liability of IBS on anxiety.

Conclusions These findings provide evidence of the polygenic architecture of IBS, identify novel hits for IBS and extend previous knowledge on the genetic overlap and relationship between gastrointestinal and mental disorders.

INTRODUCTION

Irritable bowel syndrome (IBS) is one of the most prevalent disorders of gut-brain interaction with a population lifetime risk of 11% 1 and a point prevalence of 4.1% according to the strict Rome IV criteria 2. IBS research is extremely challenging due to the multifactorial etiology of the disease and the heterogeneity of patients, who present high comorbidity rates for mental disorders, particularly, anxiety and depression, which impacts negatively on the patients’ quality of life 1,3,4.

A recent systematic review revealed that the prevalence of anxiety and depression symptoms among IBS patients is 39.1% and 28.8%, respectively 5. In addition, IBS has been associated with more severe depressive symptoms compared to healthy controls and, when co-existing with psychiatric disorders, gastrointestinal symptoms are more severe and disabling 6–11. This close association between IBS, anxiety and depression is also supported by neuroimaging studies and might be related to the bi-directional communication between the brain and the digestive system, termed the brain-gut-axis, which occurs through microbiota, neural, neuroimmune and neuroendocrine pathways 12–14. This idea agrees with evidence indicating that psychiatric interventions, including antidepressants or cognitive-behavioral therapy, improve IBS patients functioning and suggests that common pathophysiological mechanisms may be underlying these conditions 15.

IBS, anxiety and depression are partly determined by a genetic component and show substantial heritability ranging from 6% for IBS to 30%-50% for anxiety and depression 16–18. The largest GWAS on IBS conducted to date included 53,400 cases and 433,201 controls and identified six genome-wide significant loci 18 which represents an improvement over the previous study identifying four independent hits 19. Interestingly, among 173 traits, three mental conditions (neuroticism, depression and anxiety) were the most genetically correlated traits with IBS 18. Despite these strong genetic correlations, the genetic underpinnings explaining the high rates of comorbidity between IBS and mental conditions remain largely unclear and there are no conclusive data on the temporal and causal relationship between them 18,19.

In the present study we investigated the shared genetic architecture and the nature of the relationship between IBS and three highly genetically correlated conditions (neuroticism, depression and anxiety) using summary statistics of the largest GWAS datasets available so far by (i) estimating the genetic correlation and overlap between them, (ii) conducting a Multi-Trait Analysis of GWAS (MTAG) to identify novel genetic loci for IBS and (iii) performing downstream analyses to explore the overlaping genetic basis with other disorders and traits as well as causal relationships between them.

MATERIALS AND METHODS

Samples

We used publicly available SNP-level GWAS summary statistics for IBS 18, neuroticism 20, depression 21 and anxiety (Table 1). For further details see Supplementary Note 1.

View this table:
Table 1.

Summary of the GWAS datasets used in the current study.

SNP-based heritability genetic correlation and overlap

SNP heritability (h2SNP) and pair-wise genetic correlation between IBS and each mental condition was calculated using linkage disequilibrium score regression (LDSC) analysis 22. Conversion of h2SNP estimates from observed to liability scale was done using a population prevalence of 11%, 25%, 30% and 14% for IBS, neuroticism, depression and anxiety, respectively. Polygenic overlap between IBS and each mental condition was quantified using MiXeR 23. MiXeR caclulates the number of trait-influencing loci for each trait (univariate model) and for both traits (bivariate model) and the proportion of variants with concordant direction of effects for both traits. The proportion of SNPs shared by two traits is indicated by the Dice coefficient. Model fit was assessed using the Akaike Information Criterion (AIC). For further details see Supplementary Note 2.

Multi-Trait Analysis of GWAS (MTAG)

To identify new loci for IBS, SNP-level GWAS for IBS, neuroticism, depression and anxiety were meta-analyzed using MTAG 24. To discard inflation in our results we calculated the max-false discovery rate (max-FDR) using the default settings as previously described 24,25. Independent lead SNPs from MTAG-IBS results (P-value<5-E08) were identified through clumping (r2=0.05, kb=5000) using the 1000 Genomes Project Phase 3 European reference panel (http://www.internationalgenome.org/) and PLINK1.09 as described by Eijsbouts et al. 18. We carried out conditional analyses to evaluate independence between secondary (within 5000kb and r2<0.2) and index variants within each locus using COJO implemented in Genome-wide Complex Trait Analysis (GCTA) 26. For further details on conditional analysis see Supplementary Note 3.

Credible variants and functional annotation

Sets of credible variants (credible-sets) were identified by fine-mapping the independent lead SNPs of MTAG-IBS using three different tools, FINEMAP 1.3.1 27, PAINTOR v3.0 28 and CAVIARBF v.0.2.1 29 following the pipeline available elsewhere 30. Variants located in a region of 5000 kb around the lead SNPs were included in the analysis and we assumed that there was only one causal variant per locus. We used the recommended parameters of each tool and only variants identified by all three methods were considered. Functional annotation of the credible variants was conducted using FUMA31. For further details see Supplementary Note 4.

Gene-based and gene-set analyses of MTAG-IBS results

Gene-based and gene-set analyses of MTAG-IBS risk loci were performed using MAGMA v1.08 32 implemented in FUMA 31. Tissue specific gene expression was explored using MAGMA gene-property analysis of expression data from GTEx v8 and BrainSpan available in FUMA (databases detailed in Supplementary Note 5). All gene sets were obtained from the Molecular Signatures Database (MSigDB v6.2) and included GO, KEGG, BIOCARTA and Reactome representing a total of 11,960 gene sets. The Bonferroni-corrected significance threshold was 0.05/11960 gene sets=4.18E-06.

Drug target identification

To explore whether finemapped genes related with IBS were enriched for target genes of drugs (druggable genes) we performed enrichment analysis based on information from the PharmGKB using WebGestAlt 33. Identified drugs were classified according to available information from the Anatomical Therapeutic Chemical (ATC) classification system.

Partitioned heritability and genetic correlations

We partitioned h2SNP of MTAG-IBS results by functional annotation categories using stratified LDSC 34. We calculated whether any of the 28 specific genomic categories included in the analysis was enriched for variants that contribute to h2SNP. Annotations for these functional genomic categories (e.g. coding or regulatory regions) were obtained from LDSC website (https://github.com/bulik/ldsc/wiki/Partitioned-Heritability). We focused on categories extended by 500bp in either direction. Enrichment/depletion of heritability in each category is calculated as the proportion of heritability attributable to SNPs in the specified category divided by the proportion of total SNPs annotated to that category. The Bonferroni-corrected significance threshold was 0.05/28 annotations=0.0021.

We explored genetic correlations between our MTAG-IBS results and gastrointestinal, immunological and psychiatric disorders using LDSC analysis 22. We selected all GWAS summary statistics of gastrointestinal/abdominal, immunological/systemic (UK Biobank: 21 phenotypes) and psychiatric disorders (PGC: 7 phenotypes) available in the MR-Base database (Supplementary Table 14) 35. We used GWAS summary statistics including both males and females of European ancestry. If several GWAS were available for the same disorder, we chose the study with the largest effective sample size (N effective = 4NcaNco/(Nca+Nco)). The Bonferroni-corrected significance threshold used was 0.05/28 traits=0.0018.

Causal analysis using summary effect estimates (CAUSE)

Causal relationships between IBS and correlated traits were assessed considering independent variants (r2=0.05; kb=5000) associated with the exposure with P<1.0E-03 using CAUSE 36. Bidirectional relationships were tested considering IBS as exposure and depression, anxiety or neuroticism as outcomes and vice-versa. Given that SE was not available from the largest study on neuroticism to date 37, we used the GWAS dataset on neuroticism by Luciano et al. in 329,821 subjects as an alternative 38. The strengths of CAUSE involve accounting for correlated horizontal pleiotropic effects (i.e. when a variant affects the outcome and the mediator through shared heritable factors) and using a less stringent significance threshold (P<1.0E-3) allowing the incorporation of more variants to the analyses. CAUSE compares two nested models, a sharing and a causal model. Both models allow for horizontal pleiotropy (correlated pleiotropy (eta)) but only the casual model includes a causal effect parameter (gamma). The sharing and the causal model are compared against a null model and against each other. Model comparisons are carried out using the expected log pointwise posterior density (ELPD), a Bayesian model comparison approach that estimates how well the posterior distributions of a particular model are expected to predict a new set data. When P <0.05 the second model fits the data better than the first model. There is evidence of causal effects when the causal model represents a significant improvement in the model fit of the sharing model. For further details see Supplementary Note 9.

RESULTS

SNP-based heritability, genetic correlation and overlap

The latest GWAS on IBS 18, neuroticism 20, depression 21 and anxiety used herein are summarized in Table 1 and Supplementary Note 1. The estimated SNP heritability (h2SNP) was 6.9% (SE=0.004) for IBS, 14.6% (SE=0.005) for neuroticism, 9.9% (SE=0.004) for depression and 8.3% (SE=0.011) for anxiety (Table 2). We found evidence of strong genetic correlation between IBS and all three mental conditions, ranging from 53% to 68% (Table 2). Univariate MiXeR analysis revealed that IBS and neuroticism were highly polygenic, with around twelve thousand variants explaining 90% of SNP heritability (12,438 variants for IBS and 12,308 for neuroticism; Supplementary Table 1a). Bivariate MiXeR analysis showed that the majority of the variants influencing IBS were shared with neuroticism (10,793 (SE=1.094) out of 12,438 (SE=1.305) variants, Dice coefficient=0.87), with a high proportion of variants being concordant (71%) (Supplementary Table 1a and Supplementary Figure 1). Unfortunately, MiXeR was unable to accurately quantify the genetic overlap between IBS and depression or anxiety according to the Akaike Information Criterion (AIC; Supplementary Table 1b).

View this table:
Table 2.

Genetic correlation estimates for IBS and neuroticism, depression and anxiety using Linkage Disequilibrium Score Regression (LDSC).

Multi-Trait Analysis of GWAS (MTAG)

To identify novel loci for IBS, we combined the summary statistics from the GWAS on IBS, neuroticism, depression and anxiety using MTAG, increasing the estimated effective sample size from 486,601 in the original IBS dataset to 887,490. The max-FDR of MTAG-IBS analysis was low (0.020) suggesting no inflation, consistent with the similar mean chi-square values for the different GWAS, ranging from 1.08 for anxiety to 1.69 for neuroticism. After MTAG analysis, the number of genome-wide significant SNPs for IBS increased from six in the original GWAS to 42 independent SNPs in 37 loci in the current study (Figure 1, Supplementary Figure 2, Table 3 and Supplementary Table 2). Comparing these results with the ones originally described for IBS 18, 38 out of the 42 SNPs identified herein were novel for IBS and all of them showed consistent direction of the association (Figure 1a and Supplementary Table 3). Of them, 11 were not previously associated with neuroticism, depression or anxiety (Figure 1d). The remaining signals, 27 in total, were novel risk loci for IBS but previously reported for neuroticism and/or depression (Table 3, Figure 1d) and overall showed consistent direction of association with that reported in the original studies (Figure 1a). Of the six loci previously identified in IBS 18, four of them, on chromosome 3, 6, 9 and 11, were among the significant loci for IBS in the current study and the two additional ones, in chromosome 13, showed suggestive evidence of association (P<5E-07; Table 3). Among top findings, we found lead SNPs nearby genes involved in transcriptional regulation, including non-coding RNAs (RP11-629G13.1 and MSH5-SAPCD1), RNA splicing (CELF4), chromatin remodeling (EP300 and HIST1H3J), mRNA transport (FAM120A) or nucleic acid binding (TCF4 and ELAVL2), as well as in brain development (TMEM161B) or presynaptic activity (PCLO).

Figure 1.
Figure 1. MTAG results of IBS and overlap with previous GWAS on IBS, neuroticism, depression and anxiety.

a) Z-scores of MTAG-IBS and original GWAS on IBS, neuroticism, depression and anxiety for each of the independent lead SNPs (n=42) found in MTAG-IBS results. Dotted grey line indicates 0 Z-score and solid grey lines indicate statistical significance at P<5-E08. b) Manhattan plot of the MTAG-IBS results. Dotted grey line indicates statistical significance at P<5-E08. c) QQ plot of the MTAG-IBS results. d) Venn diagram depicting overlap among MTAG-IBS independent lead SNPs and genome-wide significant hits in the original GWAS.

View this table:
Table 3.

Results for the 42 independent lead SNPs identified in the MTAG-IBS analysis.

Credible variants and functional annotation

We identified a total of 1,818 Bayesian credible variants in the 37 independent loci for IBS (Supplementary Table 4). Their functional annotation revealed over-presentation of SNPs in introns (64.6%), intergenic regions (21.7%) or located in non-coding RNA (9.4%) (Figure 2 and Supplementary Table 5). A total of 75% of the variants within credible sets were located in open chromatin regions (minimum chromatin state ≤ 7), 3% were likely to affect the binding of transcription factors (RegulomeDB scores from 1b to 2c) and 0.05% may be deleterious (Combined Annotation Dependent Depletion (CADD) score > 12.37) (Figure 2 and Supplementary Table 5). Forty-eight variants were previously related by GWAS (P<5E-07) to digestive-related phenotypes (e.g. inflammatory bowel disease, gastroesophageal reflux or gut microbiota relative abundance), lifestyle factors (e.g. alcohol consumption, lifetime smoking, coffee consumption or moderate to vigorous physical activity levels) and brain and neuropsychiatric phenotypes (e.g. neuroticism, depression, anxiety, cognition or brain morphology) (Supplementary Table 6). In addition, we found that more that half of the credible variants (n=953; 52%) were expression quantitative trait loci (eQTL) for at least one gene in one brain area (n=895; 49%) and/or digestive tissue (n=690; 38%; Supplementary Table 7).

Figure 2.
Figure 2. Follow-up analysis of MTAG-IBS results and causal analysis.

a) Functional annotation of the credible variants associated with MTAG-IBS. b) RegulomeDB scores of the credible variants associated with MTAG-IBS. Low scores indicate increasing likelihood of having regulatory function. c) Distribution of the credible variants associated with MTAG-IBS across 15 categories of minimum chromatin state. Lower state indicating higher accessibility and states from 1 to 7 refer to open chromatin states. d) Genetic correlations (rg) between MTAG-IBS results and 17 phenotypes involving digestive, immunological and psychiatric disorders. Only significant correlations after Bonferroni correction are displayed. e) Bar graphs depicting the size of the genomic locus (left), number of candidate SNPs in the locus (center) and number of mapped genes in the genomic locus (right). Genomic loci are displayed by “chromosome: start position-end position “. f) Partitioning of the SNP heritability of the MTAG-IBS results using LD Score regression. Enrichment was calculated by dividing the partial heritability of a category by the proportion of SNPs in that category (proportion indicated by color). Only significant enrichments are displayed. g) Causal relationships between IBS and neuroticism, depression and anxiety assessed using Causal Analysis Using Summary Effect estimates (CAUSE). Only associations with evidence of causal relationship are displayed.

Credible variants were mapped to 289 unique genes (Supplementary Table 8) that were significantly enriched in genes upregulated during early embryonic brain development (8th post conceptual week; Supplementary Figure 3) and in several gene-sets (Supplementary Table 9). Among the most significant ones, we found psychiatric disorders (GWAS catalog: autism spectrum disorder or schizophrenia, P-adjusted=4.96E-193), digestive disorders (GWAS catalog: ulcerative colitis, P-adjusted=1.13E-57 and inflammatory bowel disease, P-adjusted=7.05E-40), autoimmune disease (KEGG: Systemic lupus erythematosus, P-adjusted=7.91E-61) and histone deacetylases (Reactome: HDACS deacetylate histones, P-adjusted=3.09E-46) (Supplementary Table 9).

Gene-based and gene-set analyses of MTAG-IBS risk loci

The gene-based analysis identified 76 significant genes, which were associated with expression changes in the cerebellum (P=5.2E-09), frontal cortex (P=9.8E-07), anterior cingulate cortex (P=1.8E-05), basal ganglia nuclei (nucleus accumbens: P=6.9E-05; caudate: P=9.7E-04) and hypothalamus (P=4.3E-04) (Supplementary Table 10, Supplementary Figure 4) as well as with gene expression during the 21st post conceptual week (P=8.5E-04) (Supplementary Figure 5). Among top findings, we found genes with a role in brain development and synaptic function, including CADM2 and NCAM1, previously identified in the latest GWAS on IBS, and also genes involved in transcriptional regulation through mRNA transport or chromatin structure, including FAM120A, PHF2 and different histone coding genes. When we conducted the gene-set analysis we found the branching morphogenesis of a nerve pathway significantly associated with IBS (gene-set size=10 genes; P= 1.7E-06) (Supplementary Table 11).

Drug target identification

The enrichment analysis on druggable genes showed enrichment of MTAG-IBS-finemapped credible genes in druggable genes for 21 drugs (Supplementary Table 12), being l-lysine (P < 2.2E-16), belinostat (P=8.6E-10), s-adenosylmethionine (P=7.0E-09) and allopurinol (P=1.5E-07), the top ones (Supplementary Table 12). They also included drugs related to musculo-skeletal system, such as anti-inflammatory and antirheumatic drugs, or related to the nervous system, such as anesthetics and drugs used in opioid dependence (Supplementary Table 12).

Partitioned heritability and genetic correlations

SNP When we partitioned the h2 of IBS, we observed significant heritability enrichment in seven functional categories (Figure 2 and Supplementary Table 13), with the strongest enrichment of variants in conserved regions (enrichment=2.01; P=4.0E-09), DNase I hypersensitive sites (DHSs) regions (enrichment=1.66; P=9.1E-08) and histone H3 lysine 9 acetylation (H3K9ac) peaks (enrichment=6.88; P=1.1E-07).

We found significant genetic correlations between IBS and 13 gastrointestinal, immunological or psychiatric disorders using GWAS summary statistics available in the MR-Base database 35, including gastric reflux (rg=0.51; P=2.6E-36), the cross-disorder GWAS from the PGC involving schizophrenia, bipolar disorder, major depressive disorder, autism spectrum disorders (ASD) and attention-deficit/hyperactivity disorder (ADHD) (rg=0.44, P=9.7E-46), diverticulitis (rg=0.44, P=7.4E-22), hiatus hernia (rg=0.43; P=4.7E-20) and chronic fatigue syndrome (rg=0.39, P=2.0E-04), among others (Figure 2 and Supplementary Table 14).

Causal analysis using summary effect estimates (CAUSE)

CAUSE 36 showed consistent evidence for a causal effect of the genetic liability of IBS on neuroticism (ΔELPD=-3.6, SE=1.9, P=0.031), depression (ΔELPD=-5.9, SE=1.8, P=5.4E-03) and anxiety (ΔELPD=-2.9, SE=1.7, P=0.049). We also found evidence for reverse causality with a causal effect of the genetic liability of neuroticism and depression on IBS (ΔELPD=-7.3, SE=1.4, P=1.5E-07 and ΔELPD=-6.3, SE=1.4, P=1.8E-06 respectively) but there was no evidence for a causal relationship when anxiety was considered as exposure and IBS as outcome (Figure 2, Supplementary Table 15a and 15b and Supplementary Figure 6).

DISCUSSION

In the present study we found extensive genetic sharing between IBS, neuroticism, depression and anxiety, and identified 42 genome-wide significant hits for IBS, of which 38 are novel. Our findings confirm the polygenic architecture of the disorder, with more than 12,000 variants explaining 90% of the h2SNP, and represent a great advance over the previously reported six genome-wide risk loci 18. Significant signal enrichment was found in genes showing heightened expression in the brain during early embryonic development and playing prominent roles in mental and digestive disorders, autoimmune diseases and transcription regulation.

Our results confirm a role on IBS of genes involved in brain development and synaptic function as well as genes previously associated with psychiatric conditions 18. We detected 27 loci for IBS also associated with at least one of the three mental conditions under study, and found evidence supporting that IBS and neuroticism, which is genetically correlated with many psychiatric disorders 39, share a considerable proportion of their genetic background. The widespread common genetic risk sharing with mental conditions was further supported by the positive genetic correlation found between IBS and many psychiatric disorders (i.e. schizophrenia, ADHD, autism or depression) and by the IBS associated variants being located within genes significantly expressed in the brain. These results are in agreement with the higher burden of mental disorders often co-existing in IBS patients, add further evidence of substantial pleiotropy of contributing loci and underscore that genetic influences on IBS may transcend diagnostic boundaries.

Among top findings we identified genes associated with IBS in previous GWAS, such as CADM2 and NCAM1, members of the synaptic cell adhesion molecules that play a role in synapse organization and plasticity 40,41. Interestingly, NCAM peptide mimetics have been proven to have both antidepressant and anti-inflammatory effects 42,43, pointing them as a potential therapeutic target for IBS. Novel loci for IBS include interesting genes previously associated with depression and other mental disorders, such as RERE, that regulates retinoic acid signaling during development 44–46, PCLO, involved in synaptic vesicle trafficking, TMEM161B 47, a brain-expressed transmembrane protein 48, RBFOX1, a splicing regulator mainly expressed in neurons, that is one of the most pleiotropic genes among psychiatric disorders 49 or DRD2, encoding the dopamine receptor D2R and one of the strongest candidates for psychiatric disorders and traits 50 Interestingly, several studies in animal models suggested an important role for dopamine signaling both in the development and progression of inflammatory bowel disease 51 and treatment with D2R agonists decreased the severity of ulcerative colitis in mice and rats 52. We also provide new insights underlying IBS, showing strong evidence of transcriptional regulation mechanisms playing a role in the disorder, including non-coding RNAs and histone modification. We found genes encoding histones and histone modifying enzymes among top findings, and enrichment of IBS associations in histone acetylation and methylation peaks and in target genes for the histone deacetylase inhibitor belinostat 53. These findings are in agreement with previous results involving chromatin modifications in maintenance of anxiety behavior and nociception and in visceral hypersensitivity induced by early-life stress 54,55. Additionally, top findings also include non-coding RNAs, an epigenetic mechanism that has been involved in, regulation of genes related with visceral pain response and intestinal permeability 56–58. These results add additional evidence towards the role of epigenetic programming in inflammation, visceral pain as well as in intestinal permeability, sensibility and motility in both humans and animal models of IBS 54,55,59,60.

Despite many of the findings pointing out neurobiological processes and mental disorders, we also detected links between IBS and gastrointestinal-related phenotypes. Fine mapping showed that 38% of the credible variants were eQTLs for at least one digestive tissue and that credible sets were located in genes enriched in different digestive disorders, including ulcerative colitis and inflammatory bowel disease. In addition, positive genetic correlations were found between IBS and gastric reflux, diverticulitis, hiatus hernia, cholelithiasis/gallstones and gastric/stomach ulcers, among others, which adds evidence on the overlap between the genetic risk for IBS and for other digestive-related disorders and traits. These findings may reflect the multi-factorial etiology proposed for IBS involving psychological factors, abnormal brain functioning and dysregulation of brain-gut interactions 15,61–63, as previously proposed in different psychiatric disorders such as depression 64.

IBS-associated signals were also enriched in target genes of relevant drugs, including l-lysine or S-adenosylmethionine. L-lysine acts as partial serotonin 5-HT4 receptor antagonist and inhibits serotonin-mediated intestinal pathologies in rats, including anxiety and stress-induced fecal excretion and severity of diarrhea 65. Interestingly, l-lysine, and other 5-HT4 receptor antagonists, are promising targets for the treatment of diarrhea-predominant IBS 66,67 and may aminorate serotonin disturbances in gut and brain that account for part of intestinal and mental disorders 65. Additional drugs of interest include S-adenosylmethionine, involved in neurotransmission signaling that has a putative antidepressant effect68,69 or allopurinol that improves inflammatory bowel disease clinical outcomes 70, among others.

Despite the high prevalence of psychiatric comorbidities reported in patients with IBS, particularly anxiety and depression, a clear temporal relationship between them has not been well established. We found evidence for a bidirectional causal effect between IBS and neuroticism or depression when accounting for correlated pleiotropy, which strengthens previous evidence 18. In addition, we found evidence for a causal effect of the genetic liability of IBS on anxiety. These findings support that IBS increases the risk of subsequent depressive and anxiety disorders described in longitudinal study designs 71 and also previous evidence supporting that prior depression raises the risk of developing IBS 72,73. We found, however, no evidence for a causal effect of the genetic liability of anxiety on IBS when accounting for correlated pleiotropy, in line with previous results 18. Although the sample size for anxiety was more limited and these results may also reflect lack of statistical power. Long term follow-up studies as well as larger datasets and sensitivity analyses are required to confirm the robustness of these results and to better understand the temporal relationship between IBS and comorbid mental conditions.

A major strength of our study is the substantial larger sample size compared with previous studies. By conducting meta-analysis of GWAS summary statistics for IBS and comorbid mental conditions with MTAG we increased the effective sample size from 486,601 in the original IBS dataset to 887,490 individuals and the number of IBS genome-wide significant loci from six in the single-trait analysis to 42. Thirty-eight of them were novel for IBS and 11 were not associated with any of the mental conditions under study, which highlight that MTAG combining GWAS on IBS and mental conditions is a robust strategy to identify trait specific genetic associations. In addition, four of the previously six identified loci were also significant in the present study 18. Even though two identified loci demonstrated less association here, their associations were still suggestive (P<5E-07) and in concordance in the direction of the effect with the original GWAS study on IBS, which supports validity of the findings across studies.

The study, however, should be considered in the context of some limitations: (i) We did not account for phenotypic overlap and cannot discard that comorbid conditions may have biased the observed results. Also, IBS is considered a highly heterogenous disorder with pathophysiological differences observed among clinical subtypes, between genders, and across age groups and geographic locations 1. Accounting for such factors may contribute to better characterize the disorder, capture its genetic background and identify overlap with other comorbid disorders that may impact on IBS risk, prognosis and clinical outcome 6; (ii) Despite the strong genetic correlation between IBS and the three mental conditions under study, MiXeR was unable to assess the genetic overlap between IBS, depression and anxiety probably due to the high polygenicity and low SNP heritability estimates for these traits (0.083 and 0.099, respectively) and the limited sample size of the original GWAS on anxiety. We cannot discard, either, that due to lack of power we did not detect IBS signals previously reported for anxiety in the original GWAS or evidence for anxiety increasing the risk for IBS in the causality analyses; (iii) Combining GWAS that differ a great deal in power may lead to inflation of FDR, according to MTAG authors 24. In this study we combined GWAS with different sample sizes, however their mean chi-squared was similar and accordingly the max-FDR estimated in our IBS analysis was 0.02, which suggested no inflation of our results. Moreover, despite increasing considerably the effective sample size for IBS through the addition of multiple mental conditions, a number of outcomes were related with gastrointestinal-related phenotypes, which further supports this approach.

In summary, we identified novel risk loci for the IBS, reveal new insights of its polygenic architecture and extended previous knowledge on the genetic overlap and causal relationships between IBS, neuroticism, depression and anxiety. Overall, we advance our understanding of the biological mechanisms underlying IBS, highlighted candidate genes related to brain development and function as well as transcriptional regulation and provide insight into the association between IBS and comorbid mental disorders.

Data Availability

All data used in the current study is publicly available. Summary statistics for IBS can be download from European Bioinformatics Institute GWAS Catalog (https://www.ebi.ac.uk/gwas/). Summary statistics for neuroticism can be downloaded from https://ctg.cncr.nl/software/summary_statistics/ and http://www.ccace.ed.ac.uk. Summary statistics for depression can be downloaded from https://datashare.ed.ac.uk/handle/10283/3203. Summary statistics for anxiety can be downloaded from http://www.nealelab.is/uk-biobank. Genotype tissue expression (GTEx v8) portal: http://www.gtexportal.org/home/datasets. BRAINEAC: http://www.braineac.org. eQTL catalogue: https://www.ebi.ac.uk/eqtl/Methods/. PsychENCODE: http://resource.psychencode.org. CommonMind Consortium (CMC/CMC): https://www.synapse.org//#!Synapse:syn5585484. WEB-based GEne SeT AnaLysis Toolkit (WebGestAlt): http://www.webgestalt.org. SNP heritability and genetic correlations: https://github.com/bulik/ldsc. MiXeR: https://github.com/precimed/mixer. Conditional analysis: https://yanglab.westlake.edu.cn/software/gcta/#COJO. Multi-Trait Analysis of GWAS (MTAG): https://github.com/omeed-maghzian/mtag). Fine-mapping: https://github.com/mulinlab/CAUSALdb-finemapping-pip. Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA): https://fuma.ctglab.nl/. Partitioned heritability: https://github.com/bulik/ldsc/wiki/Partitioned-Heritability. MR-Base database: https://github.com/MRCIEU/mrbase_casestudies. Causal Analysis Using Summary Effect estimates (CAUSE): https://jean997.github.io/cause/pipeline.html. The use of each software tools has been described in the Methods section. Analysis code and scripts used in the current study are available upon request from the corresponding

https://www.ebi.ac.uk/gwas/

https://ctg.cncr.nl/software/summary_statistics/

http://www.ccace.ed.ac.uk

https://datashare.ed.ac.uk/handle/10283/3203

http://www.nealelab.is/uk-biobank

http://www.gtexportal.org/home/datasets

http://www.braineac.org

https://www.ebi.ac.uk/eqtl/Methods/

http://resource.psychencode.org

https://www.synapse.org//#!Synapse:syn5585484

Declarations

Ethics approval and consent to participate

This article contains results derived from data from human participants collected by several studies performed by previous studies. All participants gave informed consent in all the corresponding original studies. Our study is based on the large-scale GWAS datasets, and not the individual-level data. Hence, ethical approval was not applicable.

Consent for publication

Not applicable.

Availability of data and material

All data used in the current study is publicly available. Summary statistics for IBS can be download from European Bioinformatics Institute GWAS Catalog (https://www.ebi.ac.uk/gwas/). Summary statistics for neuroticism can be downloaded from https://ctg.cncr.nl/software/summary_statistics/ and http://www.ccace.ed.ac.uk. Summary statistics for depression can be downloaded from https://datashare.ed.ac.uk/handle/10283/3203. Summary statistics for anxiety can be downloaded from http://www.nealelab.is/uk-biobank. Genotype tissue expression (GTEx v8) portal: http://www.gtexportal.org/home/datasets. BRAINEAC: http://www.braineac.org. eQTL catalogue: https://www.ebi.ac.uk/eqtl/Methods/. PsychENCODE: http://resource.psychencode.org. CommonMind Consortium (CMC/CMC): https://www.synapse.org//#!Synapse:syn5585484. WEB-based GEne SeT AnaLysis Toolkit (WebGestAlt): http://www.webgestalt.org. SNP heritability and genetic correlations: https://github.com/bulik/ldsc. MiXeR: https://github.com/precimed/mixer. Conditional analysis: https://yanglab.westlake.edu.cn/software/gcta/#COJO. Multi-Trait Analysis of GWAS (MTAG): https://github.com/omeed-maghzian/mtag). Fine-mapping: https://github.com/mulinlab/CAUSALdb-finemapping-pip. Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA): https://fuma.ctglab.nl/. Partitioned heritability: https://github.com/bulik/ldsc/wiki/Partitioned-Heritability. MR-Base database: https://github.com/MRCIEU/mrbase_casestudies. Causal Analysis Using Summary Effect estimates (CAUSE): https://jean997.github.io/cause/pipeline.html. The use of each software tools has been described in the Methods section. Analysis code and scripts used in the current study are available upon request from the corresponding authors.

Competing interests

JARQ was on the speakers bureau and/or acted as consultant for Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogi, Sincrolab, Novartis, BMS, Medice, Technofarma, Rubió and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire, Takeda, Shionogi, Bial and Medice. The Department of Mental Health chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Janssen-Cilag, Shire, Oryzon, Roche, Psious, and Rubió. ARU was on the speakers bureau and/or acted as consultant for Janssen-Cilag and Organon in tha last two years. All other authors declare no biomedical financial interests or conflicts of interest. JS has served as consultant for Noventure SL, Devintecpharma, Aboca, Reckitt, Ipsen & Pileje and discloses present and past recent scientific collaborations with Salvat, Norgine, Alfa-Sigma, Cosmo, Adare, Ordesa and Danone that do not constitute a conflict of interest in developing the content of the present manuscript. MS was on the speakers bureau and/or acted as consultant/advisory Board member for Tillotts, Menarini, Kyowa Kirin, Takeda, Biocodex, AlfaSigma, Sanofi, Janssen Immunology, Pfizer, Ferrer, BioGaia, Falk Foundation, Danone Nutricia Research, Ironwood, Genetic Analysis AS, DSM, Arena, Adnovate and Pharmanovia. He also was funded by Glycom/DSM research grants.

Funding

This work was supported by the Agència de GestióCd ‘Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-00444 and 2017SGR-1461); the Ministry of Science, Innovation and Universities (RYC2021-031324-I to J.C.D), the Instituto de Salud Carlos III (CP22/00128 to M.S.A and CP22/00026 to S.A) and the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 848228 (DISCOvERIE). This document is also an output of a project grant (Grant Agreement nº: 848228, DISCOvERIE) funded under H2020 Research Programme of the European Commission. The content of this document represents the views of the author(s) only and is his/her/their sole responsibility; it cannot be considered to reflect the views of the European Commission or any other body of the European Union. The European Commission do not accept any responsibility for use that may be made of the information it contains.

Authors’ contributions

SA, MSA, JC, LVR, NLL and MR designed and supervised the study. SA analyzed the data. SA, MSA, JC and MR wrote the manuscript draft. All authors contributed to the interpretation of results and critically reviewed the manuscript.

Abbreviations

ADHD
attention-deficit/hyperactivity disorder
AIC
Akaike Information Criterion
ASD
autism spectrum disorders
ATC
Anatomical Therapeutic Chemical
CAUSE
Causal Analysis Using Summary Effect estimates
IBS
irritable bowel syndrome
FDR
false discovery rate
ELPD
expected log pointwise posterior density
FUMA
Functional Mapping and Annotation of GWAS
GCTA
Genome-wide Complex Trait Analysis
GWAS
Genome-wide association study
h2SNP
SNP heritability
LDSC
Linkage disequilibrium score regression
MAGMA
Generalized gene-set analysis of GWAS data
MTAG
Multi-Trait Analysis of GWAS

Bibliography

  1. 1.↵
    Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014;6:71–80. http://dx.doi.org/10.2147/CLEP.S40245.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology 2021;160:99-114.e3.
    OpenUrlPubMed
  3. 3.↵
    Yeh H-W, Chien W-C, Chung C-H, et al. Risk of psychiatric disorders in irritable bowel syndrome-A nationwide, population-based, cohort study. Int J Clin Pract 2018;72:e13212.
    OpenUrlPubMed
  4. 4.↵
    Ford AC, Moayyedi P, Chey WD, et al. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol 2018;113:1–18.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2019;50:132–143.
    OpenUrlPubMed
  6. 6.↵
    Lee S, Wu J, Ma YL, et al. Irritable bowel syndrome is strongly associated with generalized anxiety disorder: a community study. Aliment Pharmacol Ther 2009;30:643–651.
    OpenUrlCrossRefPubMed
  7. 7.
    Lee C, Doo E, Choi JM, et al. The Increased Level of Depression and Anxiety in Irritable Bowel Syndrome Patients Compared with Healthy Controls: Systematic Review and Meta-analysis. J Neurogastroenterol Motil 2017;23:349.
    OpenUrlPubMed
  8. 8.
    Fond G, Loundou A, Hamdani N, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2014;264:651–660.
    OpenUrlCrossRefPubMed
  9. 9.
    Zhang QE, Wang F, Geng Q, et al. Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies. Int J Biol Sci 2018;14:1504–1512.
    OpenUrlPubMed
  10. 10.
    Hazlett-Stevens H, Craske MG, Mayer EA, et al. Prevalence of irritable bowel syndrome among university students: The roles of worry, neuroticism, anxiety sensitivity and visceral anxiety. J Psychosom Res 2003;55:501–505.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Lydiard RB. Irritable bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry 2001;62 Suppl 8:38–45; discussion 46-7.
    OpenUrl
  12. 12.↵
    Nisticò V, Rossi RE, D‘Arrigo AM, et al. Functional Neuroimaging in Irritable Bowel Syndrome: A Systematic Review Highlights Common Brain Alterations With Functional Movement Disorders. J Neurogastroenterol Motil 2022;28:185–203.
    OpenUrl
  13. 13.
    Saffouri GB, Shields-Cutler RR, Chen J, et al. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat Commun 2019;10.
  14. 14.↵
    Aguilera-Lizarraga J, Hussein H, Boeckxstaens GE. Immune activation in irritable bowel syndrome: what is the evidence? Nat Rev Immunol 2022.
  15. 15.↵
    Ford AC, Sperber AD, Corsetti M, et al. Irritable bowel syndrome. Lancet 2020;396:1675–1688. http://www.thelancet.com/article/S0140673620315488/fulltext.
    OpenUrlPubMed
  16. 16.↵
    Smoller JW. The Genetics of Stress-Related Disorders: PTSD, Depression, and Anxiety Disorders. Neuropsychopharmacology 2016;41:297–319.
    OpenUrlCrossRefPubMed
  17. 17.
    Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000;157:1552–1562.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Eijsbouts C, Zheng T, Kennedy NA, et al. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nat Genet 2021;53:1543–1552.
    OpenUrlPubMed
  19. 19.↵
    Wu Y, Murray GK, Byrne EM, et al. GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression. Nat Commun 2021;12:1146.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Nagel M, Jansen PR, Stringer S, et al. Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways. Nat Genet 2018;50:920–927.
    OpenUrlCrossRefPubMed
  21. 21.↵
    Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci 2019;22:343–352.
    OpenUrlPubMed
  22. 22.↵
    Bulik-Sullivan BK, Loh P-R, Finucane HK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet 2015;47:291–295.
    OpenUrlCrossRefPubMed
  23. 23.↵
    Frei O, Holland D, Smeland OB, et al. Bivariate causal mixture model quantifies polygenic overlap between complex traits beyond genetic correlation. Nat Commun 2019 101 2019;10:1–11.
    OpenUrlCrossRefPubMed
  24. 24.↵
    Turley P, Walters RK, Maghzian O, et al. Multi-trait analysis of genome-wide association summary statistics using MTAG. Nat Genet 2018;50:229–237.
    OpenUrlCrossRefPubMed
  25. 25.↵
    Maihofer AX, Choi KW, Coleman JRI, et al. Enhancing Discovery of Genetic Variants for Posttraumatic Stress Disorder Through Integration of Quantitative Phenotypes and Trauma Exposure Information. Biol Psychiatry 2022;91:626–636.
    OpenUrl
  26. 26.↵
    Yang J, Ferreira T, Morris AP, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet 2012;44:369–375, S1-3.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Benner C, Spencer CCA, Havulinna AS, et al. FINEMAP: efficient variable selection using summary data from genome-wide association studies. Bioinformatics 2016;32:1493–1501.
    OpenUrlCrossRefPubMed
  28. 28.↵
    Greenbaum J, Deng HW. A Statistical Approach to Fine Mapping for the Identification of Potential Causal Variants Related to Bone Mineral Density. J Bone Miner Res 2017;32:1651–1658.
    OpenUrlCrossRef
  29. 29.↵
    Chen W, Larrabee BR, Ovsyannikova IG, et al. Fine Mapping Causal Variants with an Approximate Bayesian Method Using Marginal Test Statistics. Genetics 2015;200:719–736.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    Wang J, Huang D, Zhou Y, et al. CAUSALdb: a database for disease/trait causal variants identified using summary statistics of genome-wide association studies. Nucleic Acids Res 2020;48:D807–D816.
    OpenUrlCrossRefPubMed
  31. 31.↵
    Watanabe K, Taskesen E, Van Bochoven A, et al. Functional mapping and annotation of genetic associations with FUMA. Nat Commun 2017;8:1826.
    OpenUrlCrossRefPubMed
  32. 32.↵
    de Leeuw CA, Mooij JM, Heskes T, et al. MAGMA: Generalized Gene-Set Analysis of GWAS Data. PLoS Comput Biol 2015;11:e1004219.
    OpenUrlCrossRefPubMed
  33. 33.↵
    Liao Y, Wang J, Jaehnig EJ, et al. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res 2019;47:W199–W205.
    OpenUrlCrossRefPubMed
  34. 34.↵
    Finucane HK, Bulik-Sullivan B, Gusev A, et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat Genet 2015;47.
  35. 35.↵
    Hemani G, Zheng J, Elsworth B, et al. The MR-base platform supports systematic causal inference across the human phenome. Elife 2018;7:e34408.
    OpenUrlCrossRefPubMed
  36. 36.↵
    Morrison J, Knoblauch N, Marcus JH, et al. Mendelian randomization accounting for correlated and uncorrelated pleiotropic effects using genome-wide summary statistics. Nat Genet 2020;52:740–747.
    OpenUrlPubMed
  37. 37.
    Nagel M, Jansen PR, Stringer S, et al. Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways. Nat Genet 2018 507 2018;50:920–927.
    OpenUrlCrossRefPubMed
  38. 38.
    Luciano M, Hagenaars SP, Davies G, et al. Association analysis in over 329,000 individuals identifies 116 independent variants influencing neuroticism. Nat Genet 2018;50:6–11.
    OpenUrlCrossRefPubMed
  39. 39.↵
    Anttila V, Bulik-Sullivan B, Finucane HK, et al. Analysis of shared heritability in common disorders of the brain. Science 2018;360.
  40. 40.↵
    Boutwell B, Hinds D, Agee M, et al. Replication and characterization of CADM2 and MSRA genes on human behavior. Heliyon 2017;3.
  41. 41.↵
    Lüthi A, Laurent JP, Figurovt A, et al. Hippocampal long-term potentiation and neural cell adhesion molecules L1 and NCAM. Nature 1994;372:777–779.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    Downer EJ, Cowley TR, Lyons A, et al. A novel anti-inflammatory role of NCAM-derived mimetic peptide, FGL. Neurobiol Aging 2010;31:118–128.
    OpenUrlCrossRefPubMed
  43. 43.↵
    Turner CA, Lyons DM, Buckmaster CL, et al. Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates. Neuropsychopharmacol 2018 442 2018;44:356–363.
    OpenUrl
  44. 44.↵
    Fregeau B, Kim BJ, Hernández-García A, et al. De Novo Mutations of RERE Cause a Genetic Syndrome with Features that Overlap Those Associated with Proximal 1p36 Deletions. Am J Hum Genet 2016;98:963.
    OpenUrlCrossRef
  45. 45.
    Jordan VK, Fregeau B, Ge X, et al. Genotype–phenotype correlations in individuals with pathogenic RERE variants. Hum Mutat 2018;39:666.
    OpenUrlCrossRef
  46. 46.↵
    Wray NR, Ripke S, Mattheisen M, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 2018 505 2018;50:668–681.
    OpenUrlCrossRefPubMed
  47. 47.↵
    Mbarek H, Milaneschi Y, Hottenga JJ, et al. Genome-Wide Significance for PCLO as a Gene for Major Depressive Disorder. Twin Res Hum Genet 2017;20:267–270.
    OpenUrl
  48. 48.↵
    Hyde CL, Nagle MW, Tian C, et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nat Genet 2016;48:1031–1036.
    OpenUrlCrossRefPubMed
  49. 49.↵
    Lee PH, Anttila V, Won H, et al. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell 2019;179:1469-1482.e11.
    OpenUrlCrossRefPubMed
  50. 50.↵
    Ayano G. Dopamine: Receptors, Functions, Synthesis, Pathways, Locations and Mental Disorders: Review of Literatures. J Ment Disord Treat 2016;2.
  51. 51.↵
    Kurnik-łucka M, Pasieka P, Łączak P, et al. Gastrointestinal dopamine in inflammatory bowel diseases: A systematic review. Int J Mol Sci 2021;22.
  52. 52.↵
    Tolstanova G, Deng X, Ahluwalia A, et al. Role of Dopamine and D2 Dopamine Receptor in the Pathogenesis of Inflammatory Bowel Disease. Dig Dis Sci 2015;60:2963–2975.
    OpenUrlCrossRef
  53. 53.↵
    Beck HC, Nielsen EC, Matthiesen R, et al. Quantitative proteomic analysis of post-translational modifications of human histones. Mol Cell Proteomics 2006;5:1314–1325.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    Aguirre JE, Winston JH, Sarna SK. Neonatal immune challenge followed by adult immune challenge induces epigenetic-susceptibility to aggravated visceral hypersensitivity. Neurogastroenterol Motil 2017;29:e13081.
    OpenUrl
  55. 55.↵
    Moloney RD, Stilling RM, Dinan TG, et al. Early-life stress-induced visceral hypersensitivity and anxiety behavior is reversed by histone deacetylase inhibition. Neurogastroenterol Motil 2015;27:1831–1836.
    OpenUrlCrossRefPubMed
  56. 56.↵
    Vicario M, Martínez C, Santos J. Role of microRNA in IBS with increased gut permeability. Gut 2010;59:710–712.
    OpenUrlFREE Full Text
  57. 57.
    Martínez C, Rodinõ-Janeiro BK, Lobo B, et al. Original article: miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. Gut 2017;66:1537.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    Wohlfarth C, Schmitteckert S, Härtle JD, et al. miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome. Sci Rep 2017;7:19.
    OpenUrl
  59. 59.↵
    Hong S, Zheng G, Wiley JW. Epigenetic regulation of genes that modulate chronic stress-induced visceral pain in the peripheral nervous system. Gastroenterology 2015;148:148-157.e7.
    OpenUrlCrossRefPubMed
  60. 60.↵
    Tran L, Schulkin J, Ligon CO, et al. Epigenetic modulation of chronic anxiety and pain by histone deacetylation. Mol Psychiatry 2015;20:1219–1231.
    OpenUrl
  61. 61.↵
    Staudacher HM, Mikocka-Walus A, Ford AC. Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials. Lancet Gastroenterol Hepatol 2021;6:401–410.
    OpenUrl
  62. 62.
    Carabotti M, Scirocco A, Maselli MA, et al. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol Q Publ Hell Soc Gastroenterol 2015;28:203.
    OpenUrl
  63. 63.↵
    Fadgyas-Stanculete M, Buga A-M, Popa-Wagner A, et al. The relationship between irritable bowel syndrome and psychiatric disorders: from molecular changes to clinical manifestations. J Mol Psychiatry 2014;2.
  64. 64.↵
    Evrensel A, Ceylan ME. The Gut-Brain Axis: The Missing Link in Depression. Clin Psychopharmacol Neurosci 2015;13:239–244.
    OpenUrl
  65. 65.↵
    Smriga M, Torii K. L-Lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in rats. Proc Natl Acad Sci U S A 2003;100:15370–15375.
    OpenUrlAbstract/FREE Full Text
  66. 66.↵
    Bharucha AE, Zinsmeister AR, Camilleri M, et al. Effects of a serotonin 5-HT4 receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. Gut 2000;47:667–674.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    Tam FS-., Hillier K, Bunce KT. Characterization of the 5 -hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle. Br J Pharmacol 1994;113:143–150.
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: A double-blind, randomized clinical trial. Am J Psychiatry 2010;167:942–948.
    OpenUrlCrossRefPubMedWeb of Science
  69. 69.↵
    Sharma A, Gerbarg P, Bottiglieri T, et al. S-adenosylmethionine (SAMe) for neuropsychiatric disorders: A clinician-oriented review of research. J Clin Psychiatry 2017;78:e656–e667. https://pubmed.ncbi.nlm.nih.gov/28682528/. Accessed May 18, 2022.
    OpenUrl
  70. 70.↵
    Moreau B, Clement P, Theoret Y, et al. Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD. Therap Adv Gastroenterol 2017;10:819–827.
    OpenUrl
  71. 71.↵
    Lee YT, Hu LY, Shen CC, et al. Risk of psychiatric disorders following irritable bowel syndrome: A nationwide population-based cohort study. PLoS One 2015;10:e0133283.
    OpenUrlCrossRefPubMed
  72. 72.↵
    Sibelli A, Chalder T, Everitt H, et al. A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset. Psychol Med 2016;46:3065–3080.
    OpenUrlPubMed
  73. 73.↵
    Goodwin L, White PD, Hotopf M, et al. Life course study of the etiology of self-reported irritable bowel syndrome in the 1958 British birth cohort. Psychosom Med 2013;75:202–210.
    OpenUrlAbstract/FREE Full Text
Back to top
Posted February 01, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Genome-wide multi-trait analysis of irritable bowel syndrome and related mental conditions identifies 38 new genetic hits
Silvia Alemany, María Soler Artigas, Judit Cabana, Dana Salim Fakhreddine, Natalia Llonga, Laura Vilar-Ribó, Amanda Rodríguez-Urrutia, Judit Palacio, Ana María González-Castro, Beatriz Lobo, Carmen Alonso-Cotoner, Magnus Simrén, Javier Santos, Josep Antoni Ramos-Quiroga, Marta Ribasés
medRxiv 2023.01.30.23285080; doi: https://doi.org/10.1101/2023.01.30.23285080
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area